Loading data...
Psilocybin-Research.com Searchable psilocybin and psilocin bibliometric database.

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

Research workflow

Search, filter, export, analyze, and monitor psilocybin and psilocin publications with source labels, publication status, citation links, alerts, API access, and full SQLite download.

Databases used

  • PubMed
  • Crossref
  • Europe PMC
  • OpenAlex
  • medRxiv
  • bioRxiv
  • PsyArXiv
  • ClinicalTrials.gov

Psilocybin and psilocin research index

Find psilocybin and psilocin papers, preprints, trials, and citations with clear source context.

Database 4,054 indexed records
Current display Latest publications Full SQLite index sorted by newest first. Use search or filters to narrow the list.
Database 4,054 indexed records
4,054 Total Publications 3,914 Psilocybin Records 569 Psilocin Records 569 Search Matches 826 Journals 66 Research Topics
Published 3,317 Peer-reviewed / formal records
Preprints 450 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
PubMed 278 6.9% Active
Europe PMC 1,652 40.7% Active
OpenAlex 1,401 34.6% Active
ClinicalTrials.gov 287 7.1% Active
PsyArXiv 191 4.7% Active
bioRxiv 142 3.5% Active
Crossref 69 1.7% Active
Publication timeline 3,041 dated records
3,041 records since 2020
Annual records Cumulative line
Default publication index

Latest publications

569 records from the full SQLite publication database, sorted by newest first.

Result settings and export data
Updated Jul 5, 2026 01:22 UTC
Checking for newly indexed publications...
Page 11 of 29

Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study

This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects. Psilocybin is a natural psychoactive alkaloid component of more than 200 species of naturally growing mushrooms that can be foun...

Interaction of psychedelic tryptamine derivatives with a lipid bilayer.

Naturally occurring psychedelics have been used for a long time as remedies or in religious ceremonies and recreational activities. Recent studies have proven the therapeutic potential of some psychedelic compounds to safely treat a wide range of diseases such as anxiety, depression, migraine, and addiction. It is hypothesized that psychedelic compounds like...

Effect of psilocybin on decision-making and motivation in the healthy rat.

Psilocybin and its active metabolite psilocin are hallucinogenic serotonergic agonists with high affinity for several serotonin receptors. In addition to underlying the hallucinogenic effects of these compounds, serotonin receptor activation also has important effects on decision-making and goal-directed behaviors. The impact of psilocybin and psilocin on th...

Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder

Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Be...

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.

The need to identify effective therapies for the treatment of psychiatric disorders is a particularly important issue in modern societies. In addition, difficulties in finding new drugs have led pharmacologists to review and re-evaluate some past molecules, including psychedelics. For several years there has been growing interest among psychotherapists in ps...

Unknown journal 2023-01-09 Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G

Psilocin suppresses methamphetamine-induced hyperlocomotion and acquisition of conditioned place preference via D2R-mediated ERK signaling

AIM: Psilocin is an active metabolite form of psilocybin and exerts psychoactive effects. Recent studies suggest that psilocin may have regulatory effects on abuse drugs, but the mechanisms remain unclear. In this study, we want to explore the effects of psilocin on methamphetamine (METH)-induced alterations of behavior in mice and its molecular mechanisms. ...

Conformational Landscape and Hydrogen Bonding Pattern of Psilocin: Computational Insights

Abstract Conformational analysis of psilocin, a psychedelic molecule was carried out at B3LYP/cc-pVTZ level of theory. And a global minimum was identified having highest population among all the local conformers along with second stable conformer which is 5.4 kcal/mol higher in energy than global minimum. The global mimimum is stable due to the formation of ...

Psilocin esters - An investigation of synthetic feasibility, chemical, and metabolic stability

Julia Eklund - Psilocin esters - An investigation of synthetic feasibility, chemical, and metabolic stability (psychedelic molecules, 4th-5th September 2023, Prague, Czech Republic)

Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models.

Lysergic acid Diethylamide (LSD), psilocybin, and psilocin are being intensively evaluated as potential therapeutics to treat depression, anxiety, substance use disorder, and a host of other psychiatric illnesses. Pre-clinical investigation of these compounds in rodent models forms a key component of their drug development process. In this review, we will su...

Unknown journal 2022-12-31 Ezeaka UC, Kim HJJ, Laprairie RB.

The Resurgence of Hallucinogen Drugs in Clinical Research.

Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practices. Recently, their use has expanded to other cultures. Hallucinogens are natural or synthetic substances that alter the perception of reality at nontoxic doses, producing intense psychological and physiological ef...

Unknown journal 2022-12-31 Rivera-García MT, Cruz SL.

The Potential of Psilocybe Genus Fungi to Treat Depression and Some Addictions

The therapeutic use of the substance psilocin produced by the fungi from the genus named Psilocybe has been an interesting but also controversial topic of discussion among researchers since the 1950s until now. These fungi can synthesize several alkaloids such as psilocybin, which has hallucinogenic properties, but also muscarine, which is a toxic substance ...

A Review of Synthetic Access to Therapeutic Compounds Extracted from.

Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates to the compounds contained in various -type hallucinogenic mushrooms. It is difficult, however, to obtain and purify sufficient quantities of these compounds from fungi to carry out biological studies, hence the ne...

Pharmacokinetics and Pharmacodynamics of Oral Psilocybin Administration in Healthy Participants

Psilocybin is being investigated as a potential treatment for psychiatric and neurological disorders. Only a few studies have evaluated the pharmacokinetics (PKs) of psilocybin and have used body weight-adjusted dosing. Data on PKs and the PK-pharmacodynamic (PD) relationship of fixed doses that are commonly used are unavailable. The present study characteri...

Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens

The genus Psilocybe of Basidiomycota includes more than two hundred species of mushroom-forming fungi, which are widely known for the production of the secondary metabolite psilocybin, a prodrug of its in vivo dephosphorylated active metabolite psilocin [1]. Psilocybin is being currently used in numerous clinical trials including the treatment of Major Depre...

Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism

Summary Psilocin, the active compound in Psilocybe sp. mushrooms, is a serotonergic psychedelic that has recently gained renewed interest due to its potential as a therapeutic tool. Despite promising clinical findings, the underlying signaling mechanisms and brain region-specific effects of psilocin and other psychedelic drugs remain unclear. Psilocin, like ...

Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids.

Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their concentration variability in wild-grown mushrooms. This article aimed to determine the PSB, psilocin (PS), baeocystin (BA), norbaeocystin (NB), and aeruginascin (AE) concentrations in a large sample set of mushroom...

Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields.

Humans have collected and used hallucinogenic mushrooms for ethnic medicinal, recreational, and religious purposes since before recorded history. Currently, the use of these mushrooms is illegal in most countries, but where their use is legal they are applied as self medication. Psilocybin and psilocin, two psychoactive alkaloids, are naturally synthesized b...

Unknown journal 2022-11-03 Strauss D, Ghosh S, Murray Z, Gryzenhout M.

Psilocin - The "real deal" or an extraction byproduct.

Most illicit drug casework samples at the Israel Police National Drug Laboratory are found to be mixtures of substances. Some are a mixture of an illicit drug with fillers, and others may contain more than one illicit drug. This study was triggered by a routine gas chromatography-mass spectrometry (GC-MS) analysis of an unusual casework sample. The sample ch...

Unknown journal 2022-11-03 Gutman O, Tenne D, Bretler U.

Live source coverage

4,054 indexed records across 8 active sources.

3,317Published
450Preprints
287Clinical trials
  1. PubMed 278 records · 6.9%
  2. Europe PMC 1,652 records · 40.7%
  3. OpenAlex 1,401 records · 34.6%
  4. ClinicalTrials.gov 287 records · 7.1%
  5. PsyArXiv 191 records · 4.7%
  6. bioRxiv 142 records · 3.5%
  7. Crossref 69 records · 1.7%
  8. medRxiv 34 records · 0.8%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.